Osmotica Holdings

Osmotica Pharmaceuticals is a specialty pharmaceutical company that utilizes its proprietary Osmodex drug delivery technology to develop and commercialize complex drug products. The company's portfolio historically included a range of neurology and women's health products, most notably the first-in-class ophthalmic solution Upneeq for the treatment of acquired blepharoptosis. In 2021, the company underwent a significant strategic shift, selling its legacy neurology and women's health business to Alora Pharmaceuticals for up to $170 million. Following this divestiture, the company rebranded as RVL Pharmaceuticals to focus exclusively on its aesthetics and ophthalmology assets. The Osmodex platform remains a core technology, enabling controlled-release profiles for various small molecule therapeutics. The company was originally formed through the 2016 merger of Osmotica Holdings, Vertical Pharmaceuticals, and Trigen Laboratories.